Highly Leveraged Cancer Fighters Companies
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Total Debt
| Total Debt | Efficiency | Market Risk | Exp Return | ||||
|---|---|---|---|---|---|---|---|
| 1 | BDX | Becton Dickinson and | (0.06) | 1.16 | (0.07) | ||
| 2 | REGN | Regeneron Pharmaceuticals | (0.34) | 1.75 | (0.60) | ||
| 3 | PTCT | PTC Therapeutics | 0.10 | 4.39 | 0.43 | ||
| 4 | HALO | Halozyme Therapeutics | (0.06) | 3.76 | (0.23) | ||
| 5 | BGNE | BeiGene | (0.10) | 2.68 | (0.28) | ||
| 6 | BPMC | Blueprint Medicines Corp | 0.00 | 2.33 | 0.01 | ||
| 7 | ARRY | Array Technologies | 0.00 | 5.85 | (0.01) | ||
| 8 | NVCR | Novocure | 0.18 | 7.57 | 1.40 | ||
| 9 | AGEN | Agenus Inc | (0.17) | 5.63 | (0.95) | ||
| 10 | HRTX | Heron Therapeuti | (0.01) | 7.25 | (0.10) | ||
| 11 | KPTI | Karyopharm Therapeutics | (0.09) | 4.58 | (0.42) | ||
| 12 | FGEN | FibroGen | 0.12 | 6.85 | 0.83 | ||
| 13 | MESO | Mesoblast | 0.21 | 7.48 | 1.56 | ||
| 14 | PBYI | Puma Biotechnology | 0.08 | 4.68 | 0.38 | ||
| 15 | TGTX | TG Therapeutics | 0.14 | 4.31 | 0.61 | ||
| 16 | CLLS | Cellectis SA | (0.15) | 3.29 | (0.49) | ||
| 17 | HCM | HUTCHMED DRC | (0.15) | 3.02 | (0.46) | ||
| 18 | GERN | Geron | (0.21) | 2.29 | (0.49) | ||
| 19 | IOVA | Iovance Biotherapeutics | (0.06) | 4.19 | (0.25) | ||
| 20 | SYRS | Syros Pharmaceuticals | (0.09) | 14.59 | (1.38) |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively. In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.